Yes I noticed the number and I noticed the eligibility criteria, but I wonder and I am concerned about several things. The listed LDN dose is 4.5, there is no mention of starting at a low dose. The time frame is a hurdle. I know I would not agree to possibly take a placebo for a long period with CRPS.


"Changes in pain severity-approximately 4 weeks after conclusion of treatment?" This is confusing. It sounds like 4 weeks after the end of LDN treatment pain severity will be measured. From everything I have read once LDN is stopped symptoms return.

Primary Outcome Measures:
Changes in pain severity [ Time Frame: Approximately 4 weeks after conclusion of treatment. ] [ Designated as safety issue: No ]
Daily pain reports on a 0-10 numerical rating scale for pain, where 0=no pain and 10=pain as bad as you can imagine